Albireo reports Phase II data for A4250 in cholestatic liver disease

Albireo Pharma Inc. (NASDAQ:ALBO) said A4250 was well tolerated and led to no treatment-related serious adverse events in a Phase II trial in 20 patients ages 1-17

Read the full 271 word article

User Sign In